For over 25 years, adoptive T cell transfer models of colitis have been developed to better model inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
The mechanism of IBDs in humans incorporate both innate and adaptive immune components, primarily pointing towards a largely T cell-driven pathogenic mechanism. Chemically induced models of IBD allow us to gain an understanding of innate, inflammatory pathways and how potential therapeutics could modulate this response. The T cell adoptive transfer model is unique because it allows for the dissection of T cell targeted therapies.
Join us as we introduce this validated adoptive transfer colitis model and learn about its potential use for testing immunomodulators and microbiome-oriented therapeutics.
Louise Brackenbury, PhD
Principal Scientist, Cell Biology
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.